Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...

Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon Shinyaku certain rights to two ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.0, along ...

Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and ...

K filing with the Securities and Exchange Commission (SEC) that the company has established a Collaboration and License Agreement with Nippon Shinyaku Co., Ltd. This collaboration focuses on the ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $36.00.Stay ...

Rockville’s RegenxBio Inc. (NASDAQ: RGNX) has inked an agreement with a Japanese drug company to get two of its treatment candidates to market — a deal that could be worth $810 million over time.

Regenxbio Inc (RGNX) stock saw a modest uptick, ending the day at $7.05 which represents a slight increase of $0.10 or 1.44% from the prior close of $6.95. The stock opened at $7.17 and touched a low ...

Plus: Rockville gene therapy company inks deal; Pioneering politician from Montgomery County celebrated with portrait ...

Stifel Nicolaus analyst Annabel Samimy has reiterated their bullish stance on RGNX stock, giving a Buy rating today.Stay Ahead of the ...